Effect of Dexamethasone Combined With Ondansetron on Postoperative Nausea and Vomiting in Patients With Patient-controlled Analgesia After Video-assisted Thoracoscopic Surgery
This study has been completed.
Sponsor:
Yonsei University
Information provided by:
Yonsei University
ClinicalTrials.gov Identifier:
NCT01007500
First received: November 3, 2009
Last updated: October 6, 2010
Last verified: October 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to study the effect of dexamethasone combined with ondansetron on postoperative nausea and vomiting in patients with patient-controlled analgesia after video-assisted thoracoscopic surgery.
| Condition | Intervention | Phase |
|---|---|---|
|
Nausea Vomiting |
Drug: Dexamethasone, Ondansetron |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Prevention |
Resource links provided by NLM:
MedlinePlus related topics:
Nausea and Vomiting
Drug Information available for:
Dexamethasone
Dexamethasone acetate
Dexamethasone sodium phosphate
Ondansetron hydrochloride
Ondansetron
U.S. FDA Resources
Further study details as provided by Yonsei University:
Primary Outcome Measures:
- Incidence of postoperative nausea and vomiting [ Time Frame: within 48 hrs after surgery ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 130 |
| Study Start Date: | September 2009 |
| Study Completion Date: | September 2010 |
| Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Drug: Dexamethasone, Ondansetron
Experimental: Dexamethasone 8 mg IV after induction of anesthesia, Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
Active comparator: Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
Eligibility| Ages Eligible for Study: | 20 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients undergoing video-assisted thoracoscopic surgery
- Age 20-75
- American Society of Anesthesiologists physical status classification I or II
Exclusion Criteria:
- Antiemetic within 24 hrs
- Taking Steroids, Opioids within 1 week
- Active drug or alcohol abuse
- GI motility disorder, severe renal/ hepatic disease.
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Shim, Yon Hee/associate professor, Department of Anesthesiology and Pain Medicine and Anesthesia and Pain Reseach Institute, Yonsei University College of Medicine |
| ClinicalTrials.gov Identifier: | NCT01007500 History of Changes |
| Other Study ID Numbers: | 4-2009-0407 |
| Study First Received: | November 3, 2009 |
| Last Updated: | October 6, 2010 |
| Health Authority: | Korea: Food and Drug Administration Korea: Ministry for Health, Welfare and Family Affairs |
Keywords provided by Yonsei University:
|
Postoperative nausea and vomiting after video-assisted thoracoscopic surgery |
Additional relevant MeSH terms:
|
Nausea Vomiting Postoperative Nausea and Vomiting Signs and Symptoms, Digestive Signs and Symptoms Postoperative Complications Pathologic Processes Dexamethasone acetate Dexamethasone Ondansetron Dexamethasone 21-phosphate BB 1101 Anti-Inflammatory Agents Therapeutic Uses Pharmacologic Actions |
Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Central Nervous System Agents Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antipruritics |
ClinicalTrials.gov processed this record on May 21, 2013